Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5' DFUR)on Breast Cancer

被引：11

作者：

Hata Y. ^{[1
]}

Takahashi H. ^{[2
]}

Sasaki F. ^{[2
]}

Ogita M. ^{[3
]}

Uchino J. ^{[4
]}

Yoshimoto M. ^{[5
]}

Akasaka Y. ^{[6
]}

Nakanishi Y. ^{[7
]}

Sawada Y. ^{[8
]}

机构：

[1] Sapporo Social Insurance, General Hospital, Atsubetsu-ku, Sapporo 004-8618

[2] Hokkaido University, School of Medicine

[3] National Sapporo Hospital, Hokkaido Cancer Center

来源：

Breast Cancer | 2000年 / 7卷 / 1期

关键词：

5'-Deoxy-5-fluorouracil; Breast cancer; Pyrimidine nucleoside phosphorylase;

D O I：

10.1007/BF02967186

中图分类号：

学科分类号：

摘要：

Background: Pyrimidine nucleoside phosphorylase (PyNPase) is the enzyme that converts 5'-deoxy-5-fluorouracil (5'DFUR) to 5-fluorouracil (5FU). Its activity in cancer tissue may correlate with the selective antitumor activity of 5'DFUR in breast cancer. Methods: Two hundred and sixteen T2 breast cancer patients were treated consecutively with surgery followed by 5'DFUR (600 mg/body/day)H-tamoxifen (20 mg/body/day) for 2 years. PyNPase activity in breast cancer tissue, determined by high-performance liquid chromatography, ranged from 4.2-626.0 /g FU/mg protein/hr (mean ±-SD, 203.5±122.4), and the examined patients were divided into two groups: group A (high PyNPase group), cases with the PyNPase activity equal to or more than the mean value of 203.5 μg FU/mg protein/hr, and group B (low PyNPase group), cases with activity less than the mean value. Results: Although there was no difference in relapse-free survival (RFS) between groups A and B, among node-positive patients (n=83) those in group A tended to have a longer RFS. When divided into subgroups according to estrogen receptor (ER) status, among node-positive and ER-positive tumors (n= 49), the RFS was significantly better in group A than in group B (p<O.05). Conclusion: Intratumoral PyNPase activity might be of use as a predictor of the effect of adjuvant 5'DFUR on breast cancer.

引用

页码：37 / 41

页数：4

共 13 条

[1]

Ishitsuka H., Miwa M., Takemoto K., Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine, Gann, The Japanese Journal of Cancer Research, 71, 1, pp. 112-123, (1980)

[2]

Suzuki S., Hongu Y., Fukazawa H., Et al., Tissue distribution of 5Ldeoxy-5-fluorouridine and derivated 5-furuorouracil in tumor, Jpn J Cancer Res, 71, pp. 238-245, (1980)

[3]

Furukawa K., Yoshimura A., Sumizawa T., Et al., Angiogenic factor, Nature, 356, (1992)

[4]

Usnki K., Saras J., Waltenberger J., Et al., Platelet-defived endothelial cell growth factor has thymidine phosphorylase activity, Biochem Biophys Res Commun, 184, pp. 1311-1316, (1992)

[5]

Takahashi H., Uchino J., Ogita M., Sasaki F., Hata Y., Yoshimoto M., Akasaka Y., Nakanishi Y., Sawada Y., Pyrimidine nucleoside phosphorylase activity and biological characteristics of breast cancer, International Journal of Oncology, 7, 5, pp. 1139-1144, (1995)

[6]

Peters G.J., Wets M., Ypam K., Et al., Transformation of mouse fibroblasts with the oncogenes Hras or trk is associated with pronounced changes in drug sensitivity and metabolism, Int J Cancer, 54, pp. 250-455, (1993)

[7]

Haraguchi M., Furukawa T., Sumizawa T., Akiyama S.-I., Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites, Cancer Research, 53, 23, pp. 5680-5682, (1993)

[8]

Eda H., Fujimoto K., Watanabe S., Ishikawa T., Ohiwa T., Tatsuno K., Tanaka Y., Ishitsuka H., Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5'-deoxy-5-fluorouridine, Japanese Journal of Cancer Research, 84, 3, pp. 341-347, (1993)

[9]

Iida Y., Tokuda Y., Arai K., Et al., Measurement of cytosol estrogen receptor in human breast cancer using 16a -125-estradiol, Nucl Med, 24, pp. 327-333, (1987)

[10]

Kobayashi S., Iwase H., Karamatsu S., Et al., Fundamental and clinical studies on the monoclonal EIA kit for the measurement of progesterone recepteor (PgR) in human breast cancer tissues, Morro Clinic, 36, pp. 277-281, (1988)

← 1 2 →